Insights

Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt

It’s been an interesting day on the ASX for the Australian biotech company. Here are the details
The post Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt appeared first on The Motley Fool Australia. –

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime.

Before the pause in trading, the Australian biotech company’s shares were exchanging hands at 31.5 cents apiece, an 8.6% leap from the open. The share price gain came after an update was released to the market prior to the opening bell.

What did Neuroscientific announce today?

Neuroscientific shares jumped on Thursday as the company provided an update on its EmtinB label.

According to Neuroscientific, “EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve”.

The announcement said EmtinB was shown to be effective in reducing “important biomarkers” associated with severe COVID-19. The study demonstrated Neuroscientific’s label was effective in reducing these biomarkers by “more than 50%”, versus controls.

As such, this indicates a “strong therapeutic potential” for EmtinB, “in preventing severe immune responses” from COVID-19.

Neuroscientific’s hypothesis in examining EmtinB in COVID-19 was to address the “cytokine storm” that occurs with an aggressive inflammatory response in COVID-19 infection.

For example, this “storm” results in a cascade of uncontrolled inflammation in the body, which decreases a person’s lung function. A rise in the incidence of these events has been purported with COVID-19, thereby leading Neuroscientific to conduct its trial.

The results obtained suggest EmtinB “is safe to administer in future work”, and are an important milestone for the company.

Why are Neuroscientific shares in a trading halt?

Shares paused trading just after midday on Thursday, with the company stating it was working to “finalise an announcement detailing further information in regard to the results from pulmonary studies as announced today”.

The halt will remain in place until Monday 23 August, or until the announcement is released to the market.

Neuroscientific share price snapshot

The Neuroscientific Biopharmaceuticals share price has posted a year-to-date return of 26%, extending the previous 12 months’ climb of 31%.

These returns have both outpaced the S&P/ASX 200 Index (ASX: XJO)’s gain of around 25% over the last year.

The post Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt appeared first on The Motley Fool Australia.

Should you invest $1,000 in Neuroscientific Biopharmaceuticals right now?

Before you consider Neuroscientific Biopharmaceuticals, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuroscientific Biopharmaceuticals wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Beacon Lighting (ASX:BLX) share price shines on record profit results
ASX 200 drops, Redbubble soars, TWE falls

CSL (ASX:CSL) share price charges higher on bullish broker note
Why the Rio Tinto (ASX:RIO) share price plunged 6% today
Here are 3 of the heaviest trading ASX 200 shares this Thursday

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!